Parkinsonism with intramuscular ziprasidone [2]

American Journal of Psychiatry

Volumn 162, Issue 12, 2005, Pages 2392-2393

  Bilal, Louai ^a   Tsai, Carloine ^a   Gasper, James J ^a   Ndlela, J Charles ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; OLANZAPINE; VALPROIC ACID; ZIPRASIDONE;

ADULT; BRADYKINESIA; CASE REPORT; DOSE RESPONSE; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; HUMAN; LETTER; MALE; PARANOID SCHIZOPHRENIA; PARKINSONISM; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREMOR; VIOLENCE;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PARKINSON DISEASE, SECONDARY; PIPERAZINES; SCHIZOPHRENIA, PARANOID; THIAZOLES; VIOLENCE;

EID: 28444463276     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Daniel DG, Potkin SG, Reeves KR, Swift RH, Harrigan EP: Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) 2001; 155:128-134
2. Mason MN, Johnson CE, Piasecki M: Ziprasidone-induced acute dystonia (letter). Am J Psychiatry 2005; 162:625-626
3. Ramos AE, Shytle RD, Silver AA, Sanberg PR: Ziprasidone-induced oculogyric crisis. J Am Acad Child Adolesc Psychiatry 2003; 42:1013-1014
4. Ananth J, Burgoyne KS, Niz D, Smith M: Tardive dyskinesia in 2 patients treated with ziprasidone. J Psychiatry Neurosci 2004; 29:467-469
5. Daniel DG, Zimbroff DL, Swift RH, Harrigan EP: The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int Clin Psychopharmacol 2004; 19:9-15